First, TET2 mutations are exclusively acquired in tumor cells, or, if initially acquired in hematopoietic stem cells, they are restricted to differentiated progeny that give rise to tumor cells, with no detectable mutation in other non-tumor cells (T1001 and T1006 in Fig. 3a). The gene discussed is TET2; the disease is neoplasm.